Opening book details…
Can I read The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review on EtoBox?
The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review by Yassen, Mohammad (author);Changal, Khalid (author);Busken, Joshua (author);Royfman, Rachel (author);Schodowski, Eve (author);Venkataramany, Barat (author);Khouri, Samer J. (author);Moukarbel, George V. (author) is a nonfiction available to read on EtoBox.
What is The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review about?
We aimed to assess the overall clinical impact of cardiac myosin inhibitors in hypertrophic cardiomyopathy (HCM). We performed a meta-analysis of published trials assessing the effect of cardiac myosin inhibitors (mavacamten and aficamten) on resting and Valsalva left ventricular outflow tract (LVOT) gradients and functional capacity in symptomatic HCM. The co-primary outcomes were mean percent change (mean difference [MD]) from baseline in LVOT gradient at rest and Valsalva LVOT gradient and the proportion of patients achieving New York Heart Association class improvement ≥1. The secondary outcomes included the mean percent change from baseline N-terminal pro-B-type natriuretic peptide, troponin I, and left ventricular ejection fraction (LVEF). A total of 4 studies (all randomized controlled trials, including 3 mavacamten-focused and 1 aficamtenfocused trials) involving 463 patients were included in the meta-analysis. Compared with placebo, the cardiac myosin inhibitor group demonstrated statistically significant differences in the baseline percent change in mean LVOT gradient at rest (MD À62.48, confidence interval [CI] À65.44 to À59.51, p <0.00001) and Valsalva LVOT gradient (MD
Who reads The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review?
It is typically read by self-directed learners exploring a subject in depth.
Common subject areas: history, science, philosophy, social sciences.
- Author
- Yassen, Mohammad (author);Changal, Khalid (author);Busken, Joshua (author);Royfman, Rachel (author);Schodowski, Eve (author);Venkataramany, Barat (author);Khouri, Samer J. (author);Moukarbel, George V. (author)
- Publisher
- Elsevier BV
- Published
- 2024
- Language
- EN
- Category
- nonfiction
More by Yassen, Mohammad (author);Changal, Khalid (author);Busken, Joshua (author);Royfman, Rachel (author);Schodowski, Eve (author);Venkataramany, Barat (author);Khouri, Samer J. (author);Moukarbel, George V. (author)
Similar books
- A Guide To Hypertrophic Cardiomyopathy For Patients,their Families,and Interested Physicians Third Edition — BARRY J.MARON AND LISA SALBERG, Barry J. Maron, Lisa Salberg, Eugene Braunwald, Barry J Maron (Barry Joel), (2014)
- Hypertrophic Cardiomyopathy : for Patients, Their Families, and Interested Physicians — Maron, Barry J. (Barry Joel), 1941-; Salberg, Lisa (2006)
- Subcutaneous Versus Transvenous Implantable Defibrillator in Patients with Hypertrophic Cardiomyopathy — Jankelson, Lior; Garber, Leonid; Sherrid, Mark; Massera, Daniele; Jones, Paul; Barbhaiya, Chirag; Holmes, Douglas; Knotts, Robert; Bernstein, Scott; Spinelli, Michael; Park, David; Aizer, Anthony; Chinitz, Larry (2022)
- Nanomechanical Phenotypes in Cardiac Myosin-Binding Protein C Mutants That Cause Hypertrophic Cardiomyopathy
- Hypertrophic Cardiomyopathy; A Practical Guide to Diagnosis and Management — Edited By Srilakshmi M. Adhyapak,V. Rao Parachuri
- Diagnosis and Management of Hypertrophic Cardiomyopathy : Sudden Death Prevention — edited by Barry J. Maron (2008)